Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 for L-dopa–induced dyskinesias in Parkinson's disease
2011-001092-39Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AQW051 in levodopa-induced dyskinesia (LID), Parkinson's disease (PD), sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
AQW051
03
Conditions
levodopa-induced dyskinesia (LID)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-001092-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001092-39.